Qurient Co (XKRX:115180) FCF Margin % : -244.12% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Qurient Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Qurient Co's Free Cash Flow for the three months ended in Mar. 2024 was ₩-5,157 Mil. Qurient Co's Revenue for the three months ended in Mar. 2024 was ₩2,113 Mil. Therefore, Qurient Co's FCF Margin % for the quarter that ended in Mar. 2024 was -244.12%.

As of today, Qurient Co's current FCF Yield % is -19.08%.

The historical rank and industry rank for Qurient Co's FCF Margin % or its related term are showing as below:

XKRX:115180' s FCF Margin % Range Over the Past 10 Years
Min: -3225.28 Med: -402.76 Max: -232.76
Current: -232.76

During the past 10 years, the highest FCF Margin % of Qurient Co was -232.76%. The lowest was -3225.28%. And the median was -402.76%.

XKRX:115180's FCF Margin % is ranked worse than
57.07% of 1039 companies
in the Biotechnology industry
Industry Median: -139.09 vs XKRX:115180: -232.76

Qurient Co FCF Margin % Historical Data

The historical data trend for Qurient Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qurient Co FCF Margin % Chart

Qurient Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-504.14

-301.37

-244.37

Qurient Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-292.69	-308.44	-201.61	-181.74	-244.12

Competitive Comparison of Qurient Co's FCF Margin %

For the Biotechnology subindustry, Qurient Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qurient Co's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qurient Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Qurient Co's FCF Margin % falls into.

Qurient Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Qurient Co's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-22071.003	/	9031.807
	=	-244.37 %

Qurient Co's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-5157.214	/	2112.607
	=	-244.12 %

Qurient Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of Qurient Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Qurient Co (XKRX:115180) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qurient Co Ltd (XKRX:115180) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

C-dong 8th Floor, 242, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, KOR, 13487

Website

http://www.qurient.com

Qurient Co Ltd is a South Korea based biotech company. It is engaged in network research & development business model, integrating research and drug development programs with a new mechanism. Its pipeline products include Q301 for the treatment of atopic dermatitis; Q203 treats MDR/XDR/TDR TB, and Q701 is a drug-resistant cancer immuno-oncology.

Qurient Co (XKRX:115180) Headlines

No Headlines